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OBJECTIVES The goal of this study was to test: 1) if platelet glycoprotein IIb/IIIa (GP IIb/IIIa) blockade
with abciximab bolus plus 12-h infusion reduces mortality after percutaneous coronary
intervention (PCI); 2) if prevention of early myocardial infarction (MI) after PCI is a
mechanism for reducing mortality; and 3) for risk factors for mortality after PCI.
BACKGROUND Studies of PCI suggest that MI after intervention is predictive of mortality. Abciximab, a
platelet GP IIb/IIIa receptor inhibitor, has consistently reduced the incidence of MI among
PCI patients in several trials. The presumed mechanism is prevention of platelet thrombus
associated with vessel wall injury and downstream embolization into the microcirculation.
METHODS In eight trials, 5,154 patients were randomized to a regimen comprising conventional therapy
plus a bolus of abciximab within 1 h before PCI followed by a 12-h infusion; 4,136 controls
were randomized to conventional therapy alone. Patient follow-up from six months to three
years was available. Survival differences are examined using proportional hazards regression
and survival curves.
RESULTS A hazard ratio of 0.71 (95% confidence interval 0.57 to 0.89; p 5 0.003) suggests a mortality
benefit with abciximab. The absolute reduction in mortality was estimated to be 0.5% through
30 days, 0.7% through six months, 0.9% through one year and 1.8% through three years.
Early MI explained 18% of the observed mortality benefit at one year. Multivariate regression
suggests that patients with advanced cardiovascular disease may derive the greatest mortality
benefit from abciximab.
CONCLUSIONS The evidence from 9,290 randomized PCI patients shows a mortality benefit provided by
abciximab bolus plus 12-h infusion. (J Am Coll Cardiol 2001;37:2059–65) © 2001 by the
American College of Cardiology
Percutaneous coronary interventions (PCI) using balloon
angioplasty, atherectomy or intracoronary stenting was per-
formed to improve coronary blood flow and relieve myocar-
dial ischemia in over one million patients worldwide in the
year 2000. Complications of this procedure include death,
myocardial infarction (MI) and the need for repeat revas-
cularization (either percutaneous or surgical). The acute
phase complications are a consequence of vessel wall dis-
ruption leading to arterial dissection, thrombosis with em-
bolization to the microcirculation or a combination of these
factors. Several observational studies and trials of PCI
demonstrated an association between periprocedural infarc-
tion and mortality over the course of five years (1). This
suggests that preventing periprocedural MI should reduce
long-term mortality.
Abciximab prevented acute coronary complications of
PCI in randomized trials enrolling over 12,000 patients
(2–11). In the Evaluation of 7E3 in Preventing Ischemic
Complications (EPIC) trial (2), a bolus of abciximab within
1 h before PCI plus a 12-h abciximab infusion prevented
thrombotic events in patients at high risk for ischemic
complications. Subsequently, this regimen was studied in
several thousand low- and high-risk patients in seven
additional randomized trials (3–9). More than a million
patients have been treated with this regimen worldwide
since its approval in 1994. While MI and the need for
urgent repeat revascularization were reduced in individual
studies, early mortality rates were low, and differences were
not statistically significant.
The objective of this study was to analyze mortality
differences after PCI in the eight randomized trials
including standard therapy with heparin and aspirin
(placebo) and standard therapy plus an abciximab bolus
within 60 min before PCI followed by a 12-h abciximab
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infusion. Follow-up of six months to three years from
these trials is available. This analysis includes all
follow-up from all trials.
METHODS
Population and follow-up. All follow-up data are in-
cluded from all randomized, controlled studies of patients
undergoing PCI where a 0.25 mg/kg bolus of abciximab
within 60 min before PCI followed by a 12-h infusion of
abciximab was studied. These data include the three-year
follow-up from the EPIC trial (12), one-year follow-up
from the Evaluation in PTCA to Improve Long-term
Outcome with abciximab GP IIa/IIIb blockade (EPILOG)
(13) Evaluation of Platelet Inhibition in STENTing
(EPISTENT) (14) and Intracoronary Stenting and Anti-
thrombotic Regimen-2 (ISAR-2) (7) trials and six month
follow-up from the ReoPro and Primary PTCA Organiza-
tion and Randomized Trial (RAPPORT) (5), Evaluation of
ReoPro And Stenting to Eliminate Restenosis (ERASER)
(6), Abciximab before Direct angioplasty and stenting in
Myocardial Infarction Regarding Acute and Long-term
follow-up (ADMIRAL) (8) and Controlled Abciximab and
Device Investigation to Lower Late Angioplasty Compli-
cations (CADILLAC) (9) trials. All trials were randomized
and controlled. All were double-blind with a placebo except
the ISAR-2 and CADILLAC trials, which were open-label
after randomization. In the ERASER trial, one of three
arms included an infusion of abciximab that continued for
24 h after PCI. In all other active arms considered above,
the abciximab infusion was 12 h. In each case, patients
randomized to a common intervention were compared.
Regimens with abciximab given only as a bolus or discon-
tinued early after percutaneous transluminal coronary an-
gioplasty (PTCA) were excluded from the emphasized
analyses because of the early partial return of platelet
function (15) when acute ischemic event rates are still
relatively high. No incremental benefit in the rate of death,
MI or urgent intervention was observed more than six h
after treatment discontinuation when treatment was given
as a bolus or discontinued within one h after PCI, while
incremental benefit was observed after treatment when the
infusion was continued (2,3,11,14). However, a comple-
mentary analysis included patients with abciximab regimens
not continuing for 12 h after PCI (EPIC bolus group,
C7E3 AntiPlatelet Therapy in Unstable Refractory angina
[CAPTURE] pilot trial [10], CAPTURE trial [11]). Pa-
tients in the EPISTENT trial in the balloon plus abciximab
treatment group were also included in this analysis even
though a balloon arm without abciximab was not studied.
Trials testing other compounds that block the glycoprotein
IIb/IIIa (GP IIb/IIIa) receptor in the setting of PCI
(16–18) were not included. The first two of these PCI
studies of small molecule GP IIb/IIIa inhibitors failed to
show a significant reduction of the primary end point at 30
days, suggesting differences between molecules or their
dosing. The head-to-head comparison of abciximab with
tirofiban found abciximab to produce superior results for the
composite end point of death, MI and urgent repeat
revascularization (19). In addition, the pharmacology of
abciximab is distinct: platelet function recovers only gradu-
ally with abciximab, and abciximab has a dual specificity for
the aVb3 receptor on platelets, vascular smooth muscle cells
and endothelial cells (20). Finally, an analysis combining all
trials of GP IIb/IIIa inhibition showed no late mortality
benefit with other GP IIb/IIIa inhibitors (21).
The types of patients studied were high-risk in the EPIC
trial (acute MI, unstable angina, high-risk lesion character-
istics), a broad population in the EPILOG trial (excluded
only unstable angina meeting EPIC criteria and acute MI),
acute MI in the RAPPORT, ISAR-2 and ADMIRAL
trials, patients amenable to intracoronary stent placement in
the ERASER trial, patients amenable to stent placement or
angioplasty in the EPISTENT trial, acute MI patients
amenable to stent in the CADILLAC study and unstable
angina patients in the CAPTURE trial and its pilot.
Final follow-up was performed at a fixed, prespecified
interval after randomization for all patients in each study
with the exception of the EPIC trial. The EPIC follow-up
was conducted primarily in 1995, while randomization was
done primarily in 1992. Mortality follow-up in EPIC was
complete through 2.5 to 3.5 years for 97% of patients.
Abbreviations and Acronyms
ADMIRAL 5 Abciximab before Direct angioplasty
and stenting in Myocardial Infarction
Regarding Acute and Long-term
follow-up
CABG 5 coronary artery bypass grafting
CADILLAC 5 Controlled Abciximab and Device
Investigation to Lower Late
Angioplasty Complications
CAPTURE 5 C7E3 AntiPlatelet Therapy in Unstable
REfractory angina trial
CHF 5 congestive heart failure
CI 5 confidence interval
EPIC 5 Evaluation of 7E3 in Preventing
Ischemic Complications trial
EPILOG 5 Evaluation in PTCA to Improve Long-
term Outcome with abciximab GP IIa/
IIIb blockade trial
EPISTENT 5 Evaluation of Platelet Inhibition in
STENTing trial
ERASER 5 Evaluation of ReoPro And Stenting to
Eliminate Restenosis
GP IIb/IIIa 5 glycoprotein IIb/IIIa
HR 5 hazard ratio
ISAR-2 5 Intracoronary Stenting and
Antithrombotic Regimen-2 trial
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
PTCA 5 percutaneous transluminal coronary
angioplasty
PVD 5 peripheral vascular disease
RAPPORT 5 ReoPro and Primary PTCA
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Three-years of follow-up is presented here to be consistent
with previous presentation (12).
At least one year of follow-up and other patient data were
available from the EPIC, EPILOG and EPISTENT trials.
Multivariate proportional hazards regression modeling was
performed for these studies. The association of early events
(MI, urgent PCI, urgent coronary artery bypass graft sur-
gery [CABG]) within 48 h of randomization with one-year
mortality was also examined in these trials.
Statistical methods. Analyses of all randomized patients
(intention-to-treat) are presented. Patient survival and du-
ration of follow-up were available on an individual patient
basis. Survival of abciximab and control patients was com-
pared using a proportional hazards regression model as
implemented in the PHREG procedure (SAS Institute,
Inc., Cary, North Carolina). Analyses were stratified by
study and type of device (stent or balloon) to which a patient
was assigned with a common hazard ratio (HR) assumed
across strata. A 95% confidence interval (CI) for the HR for
mortality for abciximab compared with control was com-
puted by exponentiating the ends of the 95% CI for the
regression coefficient. Corresponding p values using the
Wald method are presented. For cases where no deaths
occurred in the abciximab group, the partial likelihood was
used to compute an exact upper 95% confidence bound for
the HR. A likelihood ratio was used to test for an interac-
tion of the treatment effect with device strategy planned at
the time of randomization (stent or not); patients were
stratified by device strategy in this model. A likelihood ratio
test was also used to test for study-treatment interaction and
to test for differential treatment effect in acute MI and other
patients.
The Kaplan-Meier method was used for estimation of the
probability of death in each treatment group of each study
through the entire duration of follow-up. In addition,
combined estimates of mortality with and without abcix-
imab at 48 h, 7 days, 14 days, 30 days, 6 months and 1 year
are presented by combining the individual Kaplan-Meier
survival probability estimates. Each study was weighted by
the total number of patients included (abciximab and
control) in the analysis. This is analogous to the “age-
adjustment” method (22) and corrects for imbalances in the
proportion of patients randomized to placebo and abciximab
in different studies; such imbalances could lead to a bias in
estimates of treatment group differences.
Multivariate regression modeling with data from the
EPIC, EPILOG and EPISTENT trials included baseline
characteristics (age, gender, weight, cigarette smoking),
intervention characteristics (intervention attempted, multi-
ple segments attempted, multiple vessels attempted), history
(unstable angina within 48 h, MI within seven days, PCI,
CABG, peripheral vascular disease [PVD], stroke, hyper-
tension, diabetes, congestive heart failure [CHF]) and
treatment with abciximab. Models were stratified by study.
As in other comparisons, bolus plus infusion abcixmab was
compared with placebo for patients with a common inter-
vention; thus, the bolus group from EPIC (no 12-h abcix-
imab infusion after PCI) and the EPISTENT balloon arm
(no control balloon arm) were excluded. Because of the large
number of associations tested and the relatively small
number of deaths available, interactions with treatment
were not tested.
The one-year EPIC, EPILOG and EPISTENT data
were also used to estimate the portion of mortality benefit
explained by the early reduction in MI that abciximab
provided. The proportion of patients who had both an early
event (death, MI or urgent repeat revascularization) and
died within one year was estimated for each treatment group
using the Kaplan-Meier method; all patients were censored
except those that had an event within 48 h of randomization
and later died. The difference between treatment groups was
divided by the overall difference in mortality between
treatment groups at one year to estimate the portion of
mortality reduction explained by the treatment reduction of
early events.
RESULTS
Table 1 compares mortality among PCI patients random-
ized to standard therapy (placebo) or to an abciximab bolus
immediately before PCI followed by a 12-h infusion using
a proportional hazards regression model. Lower mortality
with abciximab was observed in each study, with a signifi-
cant reduction at one year in the EPISTENT trial when
abciximab was combined with stenting (p 5 0.043). Com-
bining studies increased the strength of evidence for a
reduction in mortality with the abciximab bolus plus 12-h
infusion compared with standard therapy as indicated by an
HR of 0.71 (95% CI: 0.57, 0.89; p 5 0.003). When the
analysis in the bottom line of Table 1 was repeated,
eliminating follow-up after one year, the association re-
mained (HR 0.74; 95% CI: 0.58, 0.94; p 5 0.012). The
association remained significant after including all
follow-up of all randomized patients according to random-
ized treatment assignment including all abciximab regimens
(HR 0.79; mortality in 193/4,801 placebo patients, 234/
7,305 abciximab patients; 95% CI: 0.65, 0.96; p 5 0.017).
This included the EPIC bolus group (54 deaths/695 ran-
domized), the CAPTURE pilot (10) with 12 weeks of
follow-up (0/30 deaths abciximab; 1/30 deaths placebo),
CAPTURE (11) with six months of follow-up (17/630
deaths abciximab; 14/635 deaths placebo) and the
EPISTENT balloon plus abciximab group (17/796 deaths).
Excluding any single trial from the final analysis in Table 1
results in a p value of no higher than 0.013. No treatment-
study interaction was found (the four smaller studies were
combined for this analysis; p 5 0.64).
Patients assigned to receive a primary stent (by random-
ization in EPISTENT, the stent substudy in EPILOG and
CADILLAC; by protocol in ERASER, ISAR-2 and
ADMIRAL) and those who were not were also analyzed
separately (Table 1). The ‘All balloon’ group includes those
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who received provisional or bailout stents since balloon
angioplasty (or atherectomy in a small number of cases) was
prespecified as the primary mode of intervention. There was
no difference in the abciximab mortality reduction between
patients assigned balloon or stent treatment (p 5 0.97).
Among balloon patients, the HR was 0.72 with 95% CI
(0.55, 0.94), whereas, among stent patients, the HR was
0.71 with 95% CI (0.48, 1.04). Similarly, no interaction was
noted in the abciximab effect among patients with MI at
baseline compared with others (p 5 0.65).
Figure 1 shows a relatively high mortality rate in each
treatment group in the first two weeks after randomization
with a somewhat lower mortality rate thereafter through six
months. The relative mortality reduction with abciximab
compared with placebo was not statistically different (p 5
0.80) in the first two weeks (HR: 0.68; 95% CI: 0.46, 1.01)
than it was after two weeks (HR: 0.73; 95% CI: 0.56, 0.96).
Table 2 displays mortality rates for different time periods.
Analyses for fixed durations of six months (p 5 0.040) and
one year (p 5 0.031) reached nominal significance. The
EPIC trial is the only trial with follow-up after one year.
Between one and three years, the absolute mortality reduc-
tion with abciximab grew from 0.21% (4.45% placebo,
4.24% abcixmab) to 1.81% (8.58% placebo, 6.77% abcix-
imab [12]).
Survival regression was performed for patients random-
ized to a 12-h infusion of abciximab after PCI and corre-
sponding controls from EPIC, EPILOG and EPISTENT;
the EPISTENT balloon/abciximab arm was excluded since
no placebo/balloon arm was studied. Three years of
follow-up from EPIC and one year of follow-up from
EPILOG and EPISTENT were included. Univariate re-
gression demonstrated the following associations with in-
creased mortality: increased age (p , 0.001), female gender
(p 5 0.047), low body weight (p 5 0.013), history of
CABG (p , 0.001), history of CHF (p , 0.001), history of
diabetes (p 5 0.004), history of cancer (p , 0.001, this was
assumed to be negative for EPISTENT patients as the data
were not collected), history of hypertension (p , 0.001), no
history of previous PCI (p 5 0.018), history of PVD (p ,
0.001), no PCI attempted (p 5 0.003), multiple vessels
attempted (p , 0.001) and placebo treatment (p 5 0.011).
Association of mortality with the following did not reach
conventional (p , 0.05) levels of significance: cigarette
smoking (p 5 0.085, lower risk for smokers), MI within
seven days before study entry (p 5 0.50), multiple segments
attempted (p 5 0.071), unstable angina within 48 h before
entry (p 5 0.92), and history of stroke (p 5 0.089).
Backwards stepwise regression was used to select variables
associated (p , 0.05) with mortality. The variables selected
were: age (p , 0.001), history of CHF (p , 0.001), history
of cancer (p , 0.001), history of hypertension (p 5 0.012),
history of PCI (p 5 0.006; lower risk for patients with
previous PCI), history of PVD (p 5 0.008), multiple vessels
attempted (p 5 0.005), intervention not attempted (p 5
Figure 1. Mortality over six months for all studies combined by patient
randomization to standard therapy (placebo) versus standard therapy plus
abciximab bolus within 1 h before percutaneous coronary intervention
followed by a 12-h infusion.
Table 1. Intention-to-Treat Analysis of Mortality Reduction With Abciximab in Studies Randomizing Patients to Standard Therapy
or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI
Study Follow-up Indication
Placebo Death Abciximab Death
Hazard Ratio
(95% CI) p Valuen % n (%)
EPIC 3 years High-risk 696 59 (8.6%) 708 47 (6.8%) 0.78 (0.53, 1.14) 0.201
EPILOG* 1 year High/low-risk 939 24 (2.6%) 1,853 32 (1.7%) 0.67 (0.40, 1.15) 0.144
EPISTENT 1 year Stent 809 19 (2.4%) 794 8 (1.0%) 0.43 (0.19, 0.97) 0.043
RAPPORT 6 months MI 242 11 (4.6%) 241 10 (4.2%) 0.91 (0.38, 2.13) 0.821
ERASER*† 6 months Stent 71 1 (1.5%) 154 0 0 (0, 8.36) —
ISAR-2 1 year MI/stent 200 17 (8.5%) 201 12 (6.0%) 0.69 (0.33, 1.45) 0.331
ADMIRAL 6 months MI/stent 151 11 (7.3%) 149 5 (3.4%) 0.45 (0.16, 1.29) 0.144
CADILLAC 6 months MI 1,028 36 (3.5%) 1,054 32 (3.1%) 0.86 (0.53, 1.38) 0.532
All balloon Balloon 2,372 116 3,293 101 0.72 (0.55, 0.94) 0.016
All stent Stent 1,764 62 1,861 45 0.71 (0.48, 1.04) 0.082
All MI MI 1,644 80 1,670 62 0.76 (0.54, 1.06) 0.100
All non-MI Non-MI 2,492 98 3,484 84 0.68 (0.51, 0.92) 0.012
All combined All 4,136 178 5,154 146 0.71 (0.57, 0.89) 0.003
*Two abciximab treatment groups are combined for EPILOG and ERASER; †Two placebo deaths were reported for ERASER (6); only one occurred within six months of
follow-up.
For acronym definitions, see Abbreviations and Acronyms box.
CI 5 confidence interval; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
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0.006) and placebo treatment (p 5 0.010). Thus, the
mortality benefit with abciximab was not altered by adjust-
ment for other factors.
The rate of early end point events (death, MI, urgent
PCI, urgent CABG within 48 h of randomization) was
reduced from 9.5% in the placebo group to 4.9% in the
abciximab group in the combined EPIC, EPILOG and
EPISTENT analysis. The risk of dying between 48 h and
one year was higher (HR 3.18; 95% CI: 2.18, 4.63) among
the patients alive at 48 h who already had experienced an
early MI or urgent intervention compared with those who
did not. This increased risk associated with early end point
events is similar to the results reported in previous studies
(1). Nevertheless, most of the observed mortality from
randomization to one year was among patients who did not
have early end point events. In the placebo group, 73% of
deaths within one year were among patients without early
events (2.17% of patients had no early event and died within
one year of a total of 2.97% of placebo patients who died);
this figure was 70% in the abciximab group (1.5% of 2.14%)
(Fig. 2). Furthermore, most mortality benefit with abcix-
imab was observed among the patients who did not have
early events: 0.83% absolute mortality benefit was observed
in the abciximab group overall (2.97% 2 2.14%), with
0.67% (2.17% 2 1.5%) or 82% of the total mortality
difference observed among the patients without death, MI
or urgent PCI or CABG within 48 h of randomization. In
order to test the association of mortality with treatment
among patients without early events, patients were censored
at the time of an event (death, MI or urgent PCI or CABG
within 48 h of randomization): one year of follow-up was
used for EPISTENT and EPILOG and three years for
EPIC. Among patients without early events, the HR for
mortality with abciximab compared with placebo patients
was 0.60 (p 5 0.002).
DISCUSSION
Summary. An abciximab bolus within 1 h before PCI plus
a 12-h infusion is estimated to reduce mortality with a HR
of 0.71 compared with standard treatment without abcix-
imab (p 5 0.003, 95% CI: 0.57, 0.89). This result was
derived using a proportional hazards model combining
maximum follow-up available for all studies with patients
undergoing PCI where randomization occurred between
placebo and an abciximab bolus within 1 h before PCI plus
a 12-h infusion thereafter. Excluding deaths during the first
two weeks of follow-up or excluding patients with death,
MI or urgent intervention within 48 h of randomization,
there was still a significant reduction in mortality with
abciximab. The association between abciximab and reduced
mortality remained statistically significant after adjusting for
demographics, medical history and the nature of the inter-
vention. One year of follow-up of the EPIC, EPILOG,
EPISTENT and ISAR-2 trials showed a 0.94% absolute
mortality benefit of abciximab treatment compared with
placebo or nine lives saved per 1,000 patients randomized.
Table 2. Mortality Over Time Among All Patients in PCI Studies Randomizing Patients to
Standard Therapy or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI
(Excludes Patients Not Randomized to a Common Intervention [EPISTENT
PTCA/Abciximab Group])
Follow-up Placebo Abciximab
Absolute
Difference
Hazard
Ratio 95% CI p Value
48 h 0.54% 0.34% 0.20% 0.64 (0.34, 1.19) 0.157
7 days 1.01% 0.72% 0.29% 0.71 (0.45, 1.10) 0.125
14 days 1.36% 0.93% 0.43% 0.68 (0.46, 1.01) 0.055
30 days 1.61% 1.14% 0.47% 0.71 (0.50, 1.01) 0.056
6 months 2.86% 2.18% 0.74% 0.76 (0.59, 0.99) 0.040
1 yr* 3.33% 2.39% 0.94% 0.72 (0.53, 0.97) 0.031
2 yr† 6.62% 5.24% 1.38% 0.79 (0.51, 1.21) 0.280
3 yr† 8.58% 6.77% 1.81% 0.78 (0.53, 1.14) 0.201
*EPIC, EPILOG, EPISTENT, ISAR-2 only; †EPIC only.
CI 5 confidence interval; PCI 5 percutaneous coronary intervention; PTCA 5 percutaneous transluminal coronary
angioplasty. For acronym definitions, see Abbreviations and Acronyms box.
Figure 2. Difference in one-year mortality in the EPIC, EPILOG and
EPISTENT trials by randomized treatment assignment partitioned among
patients with and without an early end point event (death, myocardial
infarction or urgent percutaneous coronary intervention or coronary artery
bypass grafting within 48 h of of randomization). Solid box 5 with
event , 48 h; open box 5 without event , 48 h. For acronym definitions,
see Abbreviations and Acronyms box.
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The mortality benefit was similar whether a stenting or
balloon angioplasty was performed.
Multivariate regression suggested that patients with more
advanced cardiovascular disease (older age, with CHF,
hypertension, and/or multivessel disease) were at higher risk
of mortality. Treatment interactions with risk factors for
mortality were not tested because of the relatively large
number of factors and the relatively small number of deaths
in the combined studies. The model suggests that patients
without any of these risk factors would have a low risk of
mortality regardless of treatment: that the mortality benefit
is greatest among patients with advanced cardiovascular
disease. An analysis specifically examining diabetics in the
combined EPIC, EPILOG and EPISTENT trials suggests
that diabetics might receive a particular mortality benefit
from abciximab (23). The three-year EPIC follow-up sug-
gested that those with severe unstable angina might have a
greatly reduced mortality after abciximab treatment (24).
Since patients with angina this severe were excluded from
EPILOG and may have been preferentially eliminated from
EPISTENT, the results presented here do not clarify the
relative mortality benefit among patients with acute coro-
nary syndromes at the time of PCI.
Selection of analysis presented. Although a meta-analysis
of all GP IIb/IIIa inhibition studies using many agents in
both PCI and medical therapy for unstable angina/non-Q-
wave MI showed no mortality benefit at six months (21),
differences in mortality rates among the agents included in
the meta-analysis were not presented. In this study, the HR
estimation assumed both early and late mortality were
equally reduced by abciximab. We emphasized the abcix-
imab regimen that has been most widely studied, has
demonstrated the greatest acute benefit (19,20) and is in use
worldwide. Abciximab regimens with concurrent placebo
controls using the same interventional strategy were empha-
sized, excluding the EPISTENT PTCA/abciximab group.
However, an intention-to-treat analysis of PCI studies
comparing all abciximab regimens to placebo using all
available mortality follow-up confirmed the results pre-
sented.
Possible mechanisms of benefit. It is likely that the most
frequent triggering for periprocedural MI is atherosclerotic
particulate material that is microembolized in the coronary
vasculature coupled with local vasoconstriction associated
with a platelet aggregation response (25). Abciximab blocks
platelet aggregation both at the site of plaque injury and
downstream at the site of vascular embolism. Thus, marked
lessening of necrosis is likely and the chance for developing
arrhythmic foci is reduced, which are a likely cause of the
excess late sudden death events reported in multiple series
(1). However, only 18% of the mortality benefit was
estimated to be attributable to early events, and abciximab
significantly reduced mortality (p 5 0.002) compared with
placebo among patients without early events. Thus, al-
though patients with events within 48 h after PCI are more
likely to die during follow-up, most late deaths occur among
patients without these early events. Therefore, the survival
benefit of abciximab benefit is twofold. First, early events
associated with increased mortality are prevented. Second,
survival is improved among the majority of patients under-
going PCI who do not experience early events.
The measurement of early MI using routine enzyme
measurement may not detect all early benefit provided by
abciximab. There is a possibility that some platelet emboli
not causing an infarction as defined in the trials are eventually
clinically significant and are prevented by abciximab. How-
ever, other possible factors explaining the abciximab mor-
tality benefit among patients without early MI may be
related to pharmacologic characteristics of abciximab other
than the immediate prevention of platelet aggregation in the
periprocedural period. These include prolonged, gradually
tapering platelet inhibition during the first two to three
weeks after PCI (20). This enhances microcirculatory blood
flow and improves ventricular function in patients with
ongoing plaque instability after PCI, as has been reported in
patients with acute MI undergoing intracoronary stenting
with abciximab (7). Other possibilities contributing to
improved survival include beneficial effects on longer-term
arterial passivation. Abciximab blocks not only GP IIb/IIIa
on platelets but also has equivalent blocking affinity for the
aVb3 receptor (20,26) on platelets, vascular smooth muscle
cells and endothelial cells and, in addition, has demonstrable
inhibition of the Mac-1 receptor on activated monocytes
and macrophages (27). These integrin receptors and cells
have been implicated in both the acute and chronic response
to arterial plaque injury and atherothrombosis (28–31). By
blocking these receptors with tapered recovery after PCI,
abciximab may affect long-term vessel healing and stability.
Study limitations. Analysis of mortality across studies was
not prespecified. Only the EPIC trial had follow-up of more
than one year. The patient populations in these studies
varied in their enrollment characteristics. The nature of PCI
changed over the span of several years when these studies
were conducted, with stenting rarely being used at the time
of EPIC to its becoming a standard of care at the time of
EPISTENT. Although there have been over 20,000 pa-
tients in studies of GP IIb/IIIa inhibitors cited here, there
are still too few deaths in these studies to adequately assess
whether there is a differential mortality benefit between
agents, regimens and patient populations. Analyses where
early follow-up is excluded should be considered descriptive.
Despite these limitations, a mortality reduction was ob-
served consistently across time periods, devices and trials,
suggesting that the results can be generalized to a broad
patient population undergoing PCI with the abciximab
bolus plus 12-h infusion regimen.
Conclusions. The accumulated data from randomized
clinical trials provides robust evidence of a mortality benefit
provided by a bolus of abciximab within 1 h before PCI
followed by a 12-h infusion. Further follow-up to extend
the long-term observational window would be worthwhile.
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